#ESMO20: It’s not just Keytruda anymore — Merck spotlights 3 top early-stage cancer drugs
Any $12 billion megablockbuster in the portfolio tends to overshadow everything else in the pipeline. Which is something Merck can tell you a little bit about.
Keytruda not only dominates the PD-(L)1 field, it looms over everything Merck does, to the point some analysts wonder if Merck is a one-trick pony.
There’s no shortage of Keytruda data on display at ESMO this weekend, but now the focus is shifting to the future role of new drugs and combos in maintaining that lead position for years to come. And the pharma giant has a special focus for 3 early-stage efforts where Roger Perlmutter’s oncology team is placing some big bets.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,000+ biopharma pros reading Endpoints daily — and it's free.